Dels

North America Leads the Way in the Global DNA Encoded Library Market, Capturing Over 70% of Market Share by 2035 - ResearchAndMarkets.com

Retrieved on: 
Monday, October 23, 2023
Research, Technology, Neurology, Genetics, Biotechnology, Pharmaceutical, Health, Science, Oncology, Artificial Intelligence, Bristol Myers Squibb, AstraZeneca, Patent, Region, Janssen, Intellectual property, Jaden Philogene, Intellectual, DNA, Drug development, Artificial intelligence, Wuxi, Novartis, Machine learning, DNA-encoded chemical library, DEL, GenScript Biotech, Amgen, Drug discovery, GSK, Chem, DSM-IV codes, Services marketing, USD, Roche, Sanofi, Library, Therapy, Fine chemical, Pharmaceutical industry, Medical device, Computer data storage, Pfizer, Florence Provendier, Dels

With robust innovation and substantial financial support from investors, the DNA encoded library market is poised for remarkable expansion.

Key Points: 
  • With robust innovation and substantial financial support from investors, the DNA encoded library market is poised for remarkable expansion.
  • Market Analysis and Regional Dominance:
    The global DNA encoded library market is estimated to reach USD 840 million in 2023.
  • North America is expected to hold the largest market share, with more than 70% of the market captured by players based in North America and Europe by 2035.
  • Leading DNA Encoded Library Companies:
    Key players in the DNA encoded library market include BOC Sciences, DyNAbind, Edelris, GenScript, HitGen, NovAliX, PROVendis, SpiroChem, Vipergen, WuXi AppTec, and X-Chem.

AI and DNA-Encoded Libraries Synergy: Transforming Drug Discovery, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Tuesday, October 17, 2023
AI, Artificial intelligence, Drug discovery, De novo, DEL, Behavior, Dels, Chem, Medical device

TORONTO, Oct. 17, 2023 /PRNewswire-PRWeb/ -- Discover a groundbreaking webinar delving into the integration of AI and DEL technology to accelerate drug discovery. AI has emerged as a transformative force in drug discovery. By analyzing vast datasets, AI can predict the properties and behavior of small molecules, accelerating the search for new medicines. However, AI is only as good as the data it learns from. This is where DELs come in – screening generates massive high-quality datasets to train AI models, enabling accurate predictions for drug hunters.

Key Points: 
  • In this free webinar, learn about DNA-encoded libraries (DELs) and how they generate high-quality data that is valuable for training artificial intelligence (AI) models.
  • The speaker will share how the AI platform integrates all these capabilities in an easy-to-use interface to enable drug hunters to enable better and faster drug discovery.
  • TORONTO, Oct. 17, 2023 /PRNewswire-PRWeb/ -- Discover a groundbreaking webinar delving into the integration of AI and DEL technology to accelerate drug discovery.
  • This is where DELs come in – screening generates massive high-quality datasets to train AI models, enabling accurate predictions for drug hunters.

HitGen Enters into DNA-Encoded Library Based Research Service Agreement with Nested Therapeutics

Retrieved on: 
Thursday, August 10, 2023
Shanghai Stock Exchange, Dels, Cancer, Research, Organization, SSE, Patient, DEL, Drug discovery, Pharmaceutical industry, Nested

CHENGDU, China, Aug. 10, 2023 /PRNewswire/ -- Shanghai Stock Exchange listed company HitGen Inc. ("HitGen", SSE: 688222.SH) today announced that it has entered into a research service agreement with Nested Therapeutics, Inc. ("Nested"), a biotechnology company pioneering a next-generation precision medicine platform to address hard-to-treat cancers, under which HitGen will utilize its DNA-encoded library (DEL) technology platform, centered around the design, synthesis and screening of DELs, to identify hits against targets of interest to Nested.

Key Points: 
  • CHENGDU, China, Aug. 10, 2023 /PRNewswire/ -- Shanghai Stock Exchange listed company HitGen Inc. ("HitGen", SSE: 688222.SH) today announced that it has entered into a research service agreement with Nested Therapeutics, Inc. ("Nested"), a biotechnology company pioneering a next-generation precision medicine platform to address hard-to-treat cancers, under which HitGen will utilize its DNA-encoded library (DEL) technology platform, centered around the design, synthesis and screening of DELs, to identify hits against targets of interest to Nested.
  • HitGen is a world leader in the development of DEL technology and applications to early-stage small molecule drug discovery.
  • "We look forward to working with the research teams at Nested to generate novel starting points for their research programs to help address the unmet needs of patients with cancer.
  • We look forward to delivering useful outcome for Nested's research programmes," said Dr. Jin Li, Chairman of the Board and Chief Executive Officer of HitGen Inc.

HitGen Enters into DNA-Encoded Library Based Research Service Agreement with Nested Therapeutics

Retrieved on: 
Thursday, August 10, 2023
Shanghai Stock Exchange, Dels, Cancer, Research, Organization, SSE, Patient, DEL, Drug discovery, Pharmaceutical industry, Nested

CHENGDU, China, Aug. 10, 2023 /PRNewswire/ -- Shanghai Stock Exchange listed company HitGen Inc. ("HitGen", SSE: 688222.SH) today announced that it has entered into a research service agreement with Nested Therapeutics, Inc. ("Nested"), a biotechnology company pioneering a next-generation precision medicine platform to address hard-to-treat cancers, under which HitGen will utilize its DNA-encoded library (DEL) technology platform, centered around the design, synthesis and screening of DELs, to identify hits against targets of interest to Nested.

Key Points: 
  • CHENGDU, China, Aug. 10, 2023 /PRNewswire/ -- Shanghai Stock Exchange listed company HitGen Inc. ("HitGen", SSE: 688222.SH) today announced that it has entered into a research service agreement with Nested Therapeutics, Inc. ("Nested"), a biotechnology company pioneering a next-generation precision medicine platform to address hard-to-treat cancers, under which HitGen will utilize its DNA-encoded library (DEL) technology platform, centered around the design, synthesis and screening of DELs, to identify hits against targets of interest to Nested.
  • HitGen is a world leader in the development of DEL technology and applications to early-stage small molecule drug discovery.
  • "We look forward to working with the research teams at Nested to generate novel starting points for their research programs to help address the unmet needs of patients with cancer.
  • We look forward to delivering useful outcome for Nested's research programmes," said Dr. Jin Li, Chairman of the Board and Chief Executive Officer of HitGen Inc.

DNA-Encoded Libraries (DELs) and NanoBRET Target Engagement Assays Accelerate Drug Discovery

Retrieved on: 
Tuesday, August 1, 2023
Biotechnology, Other Health, Health, Science, Research, DNA, Partnership, Therapy, Aurora kinase A, Workflow, Cell Chemical Biology, Dels, Structural Genomics Consortium, Promega, Protein, DEL, Cancer, Drug discovery, Wuxi, Pharmaceutical industry, Microscope

A new study demonstrates how the combination of DNA-encoded libraries (DELs) and NanoBRET Target Engagement technology can accelerate early-stage drug discovery.

Key Points: 
  • A new study demonstrates how the combination of DNA-encoded libraries (DELs) and NanoBRET Target Engagement technology can accelerate early-stage drug discovery.
  • This research opens new opportunities to develop novel NanoBRET Target Engagement Assays aimed at many understudied classes of proteins, rapidly accelerating “hit to lead” efforts in identifying new potential therapeutics.
  • These probes would be used in a NanoBRET Target Engagement Assay, a tool for studying the interaction between a chemical compound and its target protein in live cells.
  • Additionally, they note that the NanoBRET assays help drug discovery researchers accelerate their workflow by providing data used to identify the most promising leads.

Eleven Therapeutics Announces Research Collaboration with Novo Nordisk to Discover Cell-Specific Carriers of Nucleic Acid Therapeutics

Retrieved on: 
Monday, July 17, 2023
Therapy, Novo Nordisk, Biotechnology, Dels, Research, RNA, Patient, Medicine, Artificial intelligence, Pharmaceutical industry

Through this collaboration, the companies aim to identify novel molecules that promote precise delivery of nucleic acid by leveraging Eleven's innovative DELiveri™ platform, ushering in a new era of precision in nucleic acid medicine for cardiometabolic diseases.

Key Points: 
  • Through this collaboration, the companies aim to identify novel molecules that promote precise delivery of nucleic acid by leveraging Eleven's innovative DELiveri™ platform, ushering in a new era of precision in nucleic acid medicine for cardiometabolic diseases.
  • Nucleic acid therapeutics have immense potential for cardiometabolic diseases.
  • This collaboration provides Novo Nordisk with exclusivity for specific cell types and applications associated with Eleven's innovative DELiveri™ platform in a staged approach.
  • Prof. Yaniv Erlich, CEO of Eleven Therapeutics, remarked, "We are delighted to collaborate with Novo Nordisk, a leader in global healthcare.

Eleven Therapeutics Announces Research Collaboration with Novo Nordisk to Discover Cell-Specific Carriers of Nucleic Acid Therapeutics

Retrieved on: 
Monday, July 17, 2023
Therapy, Novo Nordisk, Biotechnology, Dels, Research, RNA, Patient, Medicine, Artificial intelligence, Pharmaceutical industry

Through this collaboration, the companies aim to identify novel molecules that promote precise delivery of nucleic acid by leveraging Eleven's innovative DELiveri™ platform, ushering in a new era of precision in nucleic acid medicine for cardiometabolic diseases.

Key Points: 
  • Through this collaboration, the companies aim to identify novel molecules that promote precise delivery of nucleic acid by leveraging Eleven's innovative DELiveri™ platform, ushering in a new era of precision in nucleic acid medicine for cardiometabolic diseases.
  • Nucleic acid therapeutics have immense potential for cardiometabolic diseases.
  • This collaboration provides Novo Nordisk with exclusivity for specific cell types and applications associated with Eleven's innovative DELiveri™ platform in a staged approach.
  • Prof. Yaniv Erlich, CEO of Eleven Therapeutics, remarked, "We are delighted to collaborate with Novo Nordisk, a leader in global healthcare.

HitGen Announces Drug Discovery Research Agreement with ARase Therapeutics

Retrieved on: 
Thursday, May 18, 2023
Drug development, ADP-ribosylation, Shanghai Stock Exchange, ADP, Biotechnology, Dels, Research, Organization, SSE, DEL, Drug discovery, Therapy, Pharmaceutical industry

CHENGDU, China, May 18, 2023 /PRNewswire/ -- Shanghai Stock Exchange listed company HitGen Inc. ("HitGen", SSE: 688222.SH) announced today that it has entered into a research agreement with ARase Therapeutics, Inc. ("ARase"), a biotechnology company developing first-in-class therapeutics targeting ADP-ribose hydrolases, novel targets that function in therapeutically proven cancer stress pathways.

Key Points: 
  • CHENGDU, China, May 18, 2023 /PRNewswire/ -- Shanghai Stock Exchange listed company HitGen Inc. ("HitGen", SSE: 688222.SH) announced today that it has entered into a research agreement with ARase Therapeutics, Inc. ("ARase"), a biotechnology company developing first-in-class therapeutics targeting ADP-ribose hydrolases, novel targets that function in therapeutically proven cancer stress pathways.
  • HitGen is a world leader in the development of DEL technology and applications to early-stage small molecule drug discovery.
  • "I am delighted to see HitGen and ARase enter this drug discovery research collaboration.
  • We look forward to working together with ARase research teams progressing their therapeutic programmes for serious unmet medical needs," said Dr. Jin Li, Chairman of the Board and CEO of HitGen Inc.

HitGen Announces Drug Discovery Research Agreement with ARase Therapeutics

Retrieved on: 
Thursday, May 18, 2023
Drug development, ADP-ribosylation, Shanghai Stock Exchange, ADP, Biotechnology, Dels, Research, Organization, SSE, DEL, Drug discovery, Therapy, Pharmaceutical industry

CHENGDU, China, May 18, 2023 /PRNewswire/ -- Shanghai Stock Exchange listed company HitGen Inc. ("HitGen", SSE: 688222.SH) announced today that it has entered into a research agreement with ARase Therapeutics, Inc. ("ARase"), a biotechnology company developing first-in-class therapeutics targeting ADP-ribose hydrolases, novel targets that function in therapeutically proven cancer stress pathways.

Key Points: 
  • CHENGDU, China, May 18, 2023 /PRNewswire/ -- Shanghai Stock Exchange listed company HitGen Inc. ("HitGen", SSE: 688222.SH) announced today that it has entered into a research agreement with ARase Therapeutics, Inc. ("ARase"), a biotechnology company developing first-in-class therapeutics targeting ADP-ribose hydrolases, novel targets that function in therapeutically proven cancer stress pathways.
  • HitGen is a world leader in the development of DEL technology and applications to early-stage small molecule drug discovery.
  • "I am delighted to see HitGen and ARase enter this drug discovery research collaboration.
  • We look forward to working together with ARase research teams progressing their therapeutic programmes for serious unmet medical needs," said Dr. Jin Li, Chairman of the Board and CEO of HitGen Inc.

Philogen Announces Publication of a New Study in Collaboration with Google focused on Machine Learning models applied to DNA-Encoded Chemical Library Technology

Retrieved on: 
Tuesday, March 28, 2023
Tissue, Antigen, Intellectual property, DNA, Chemical library, Renal cell carcinoma, Dels, Ligand, Research, HIT, Blood, Protein, CAIX, Machine learning, DEL, Carbonic anhydrase, Drug discovery, Artificial intelligence, Neoplasm, Hypoxia, DNA-encoded chemical library, Vaccine, Pharmaceutical industry, Jaden Philogene

Siena, Italy, March 28, 2023 - Philogen S.p.A., a clinical-stage biotechnology company focused on the development of innovative antibody and small molecule ligands, announces the publication of a new study conducted in collaboration with Google focused on the use of Machine Learning models applied to the screening of DNA-Encoded Chemical Libraries (DELs).

Key Points: 
  • Siena, Italy, March 28, 2023 - Philogen S.p.A., a clinical-stage biotechnology company focused on the development of innovative antibody and small molecule ligands, announces the publication of a new study conducted in collaboration with Google focused on the use of Machine Learning models applied to the screening of DNA-Encoded Chemical Libraries (DELs).
  • The technology allows the rapid selection of specific binders (“Phenotype”), physically connected to unique DNA tags (“Genotype”) that work as amplifiable identification barcodes.
  • Philochem has synthesized several DNA-Encoded Chemical Libraries, featuring different designs, that have yielded high affinity and selective binders to a variety of target proteins of pharmaceutical interest.
  • These ligands - human monoclonal antibodies or small organic molecules - are identified using Antibody Phage Display Libraries and DNA-Encoded Chemical Library technologies.